Press Releases

Press Releases

October 30 | 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 30, 2019-- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in
June 18 | 2019
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory diseases, today announced that it secured an additional $37 million in an extension of its Series C
May 24 | 2019
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--FLX Bio, a clinical-stage, immunology-based biopharmaceutical company, today announced it has changed its name to RAPT Therapeutics, Inc., to more accurately represent the company’s dedication and focused efforts to develop and commercialize oral
March 5 | 2019
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target immune drivers of cancer and other immune-related disorders, today announced that Brian Wong, M.D., Ph.D., CEO will present
Displaying 1 - 10 of 11